Calendario de promoción Neuren Pharmaceuticals Limited
Horario avanzado
gráfico sencillo
Acerca de la empresa Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. más detalles| Industry | Biotechnology |
|---|---|
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | aud |
| Сайт | https://www.neurenpharma.com |
| Цена ао | 7.25 |
| Cambio de precio por día: | 0% (7.25) |
|---|---|
| Cambio de precio por semana.: | -6.58% (7.7607) |
| Cambio de precio por mes: | -13.28% (8.36) |
| Cambio de precio en 3 meses.: | -9.38% (8) |
| Cambio de precio en seis meses: | -21.88% (9.28) |
| Cambio de precio por año: | -48.21% (14) |
| Cambio de precio en 3 años.: | +137.35% (3.0545) |
| Cambio de precio en 5 años.: | +279.58% (1.91) |
| Cambio de precio desde principios de año.: | -11.8% (8.22) |
|
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
|||||||||||||||||||||||||||||||||||||
| Instituciones | Volumen | Compartir, % |
|---|---|---|
| Vanguard International Stock Index-Total Intl Stock Indx | 1480133 | 1.16 |
| Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 877162 | 0.69 |
| iShares Core MSCI EAFE ETF | 652944 | 0.51 |
| iShares MSCI EAFE Small Cap ETF | 436465 | 0.34 |
| Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 403572 | 0.32 |
| Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 215442 | 0.17 |
| iShares Core MSCI Total International Stock ETF | 140892 | 0.11 |
| Vanguard International Stock Index-Pacific Stock Index | 128668 | 0.1 |
| College Retirement Equities Fund-Stock Account | 85378 | 0.07 |
| SEI Institutional International Tr-International Equity | 71485 | 0.06 |
| Supervisor | Título profesional | Pago | año de nacimiento |
|---|---|---|---|
| Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A. | CEO, MD & Executive Director | 714.28k | |
| Ms. Lauren Frazer C.A. | CFO & Company Secretary | N/A | |
| Mr. Lawrence Glass BA (Biology) | Chief Science Officer | N/A | |
| Mr. Gerry Zhao | Vice President of Corporate Development | N/A | |
| Dr. Liza A. Squires M.D. | Chief Medical Officer | N/A |
DIRECCIÓN: Australia, Camberwell, 697 Burke Road - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.neurenpharma.com
Sitio web: https://www.neurenpharma.com
